DEDICATED TO WORKING FOR YOUR BETTER LIFE
About us
Our company Metaboli Med s.r.o. was established in 2012 with a clear mission: to contribute to healthcare by providing high-quality pharmaceutical solutions, with a particular focus on rare metabolic diseases. Since our foundation, we have become a respected and trusted name in the pharmaceutical industry, known for our commitment to innovation, compliance, and patient-centered care.
We are a proud partner of a Scandinavian pharmaceutical company POA Pharma Scandinavia AB in the Slovak Republic, with a shared focus on rare metabolic disorders, aiming to bring innovative treatments to patients. This strategic partnership enables us to expand our capabilities, exchange knowledge, and maintain the highest levels of product quality and innovation.
We specialize in the development, manufacturing, and distribution of pharmaceutical products targeting rare metabolic disorders. These conditions, though often overlooked due to their low prevalence, represent serious medical challenges that require precise and effective treatment. Our team of experts works closely with healthcare providers and researchers to develop therapies that improve the quality of life for patients with these rare conditions.
As manufacturers, we currently offer for international sale a highly innovative, high-quality product called GMP PURE Vanilla. This product is designed to support the dietary management of phenylketonuria (PKU). We believe in building long-term relationships based on transparency, trust, and shared values — whether with healthcare professionals, patients, regulatory authorities, or global partners. Together, we strive to make a meaningful impact in the lives of those affected by rare metabolic diseases and contribute to a healthier, more inclusive future in medicine.
If you are interested in cooperation or would like more information, please do not hesitate to contact us. We look forward to exploring potential collaboration opportunities.
About us
Our company Metaboli Med s.r.o. was established in 2012 with a clear mission: to contribute to healthcare by providing high-quality pharmaceutical solutions, with a particular focus on rare metabolic diseases. Since our foundation, we have become a respected and trusted name in the pharmaceutical industry, known for our commitment to innovation, compliance, and patient-centered care.
We are a proud partner of a Scandinavian pharmaceutical company POA Pharma Scandinavia AB in the Slovak Republic, with a shared focus on rare metabolic disorders, aiming to bring innovative treatments to patients. This strategic partnership enables us to expand our capabilities, exchange knowledge, and maintain the highest levels of product quality and innovation.
We specialize in the development, manufacturing, and distribution of pharmaceutical products targeting rare metabolic disorders. These conditions, though often overlooked due to their low prevalence, represent serious medical challenges that require precise and effective treatment. Our team of experts works closely with healthcare providers and researchers to develop therapies that improve the quality of life for patients with these rare conditions.
As manufacturers, we currently offer for international sale a highly innovative, high-quality product called GMP PURE Vanilla. This product is designed to support the dietary management of phenylketonuria (PKU). We believe in building long-term relationships based on transparency, trust, and shared values — whether with healthcare professionals, patients, regulatory authorities, or global partners. Together, we strive to make a meaningful impact in the lives of those affected by rare metabolic diseases and contribute to a healthier, more inclusive future in medicine.
If you are interested in cooperation or would like more information, please do not hesitate to contact us. We look forward to exploring potential collaboration opportunities.
YOU ARE OUR INSPIRATION
Phenylketonuria
Phenylketonuria (PKU) is a rare genetic disorder that causes a buildup of phenylalanine (an amino acid) in the body. It occurs when the body is unable to break down phenylalanine properly due to a deficiency in the enzyme phenylalanine hydroxylase. If left untreated, PKU can lead to severe brain damage and other cognitive issues. Fortunately, PKU can be managed with early detection and a strict diet.
Newborns typically show no symptoms at birth, which is why newborn screening is essential to diagnose the disorder early. In most countries, newborn screening is standard practice, where babies are tested for PKU just a few days after birth. A blood sample is taken to measure the level of phenylalanine. If levels are high, further tests are done to confirm the diagnosis.
While there is no cure for PKU, early diagnosis and treatment can prevent or reduce the severity of symptoms. The primary treatment for PKU is a special diet that restricts phenylalanine intake. Foods that are high in phenylalanine, such as meat, fish, dairy, eggs, and nuts, must be avoided or strictly limited.
With proper treatment, most individuals with PKU can lead normal, healthy lives. However, it requires constant management of diet and regular monitoring of phenylalanine levels. If treatment is started early and followed rigorously, individuals can avoid the severe developmental and neurological complications associated with untreated PKU.
Phenylketonuria (PKU) is a serious genetic disorder, but with modern treatments, individuals with PKU can live healthy lives. Early diagnosis through newborn screening and adherence to a strict, lifelong diet are crucial for managing the condition and preventing complications. Ongoing research is promising, and new treatments such as gene therapy may one day offer additional options for people with PKU.
Phenylketonuria
Phenylketonuria (PKU) is a rare genetic disorder that causes a buildup of phenylalanine (an amino acid) in the body. It occurs when the body is unable to break down phenylalanine properly due to a deficiency in the enzyme phenylalanine hydroxylase. If left untreated, PKU can lead to severe brain damage and other cognitive issues. Fortunately, PKU can be managed with early detection and a strict diet.
Newborns typically show no symptoms at birth, which is why newborn screening is essential to diagnose the disorder early. In most countries, newborn screening is standard practice, where babies are tested for PKU just a few days after birth. A blood sample is taken to measure the level of phenylalanine. If levels are high, further tests are done to confirm the diagnosis.
While there is no cure for PKU, early diagnosis and treatment can prevent or reduce the severity of symptoms. The primary treatment for PKU is a special diet that restricts phenylalanine intake. Foods that are high in phenylalanine, such as meat, fish, dairy, eggs, and nuts, must be avoided or strictly limited.
With proper treatment, most individuals with PKU can lead normal, healthy lives. However, it requires constant management of diet and regular monitoring of phenylalanine levels. If treatment is started early and followed rigorously, individuals can avoid the severe developmental and neurological complications associated with untreated PKU.
Phenylketonuria (PKU) is a serious genetic disorder, but with modern treatments, individuals with PKU can live healthy lives. Early diagnosis through newborn screening and adherence to a strict, lifelong diet are crucial for managing the condition and preventing complications. Ongoing research is promising, and new treatments such as gene therapy may one day offer additional options for people with PKU.
